Underwriting AgreementUnderwriting Agreement • October 25th, 2007 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Protalix BioTherapeutics, Inc., a Florida corporation (the ‘‘Company’’), proposes to issue and sell to the underwriters named in Schedule A annexed hereto (the ‘‘Underwriters’’), for whom you are acting as representative, an aggregate of 10,000,000 shares (the ‘‘Firm Shares’’) of common stock, $.001 par value per share (the ‘‘Common Stock’’), of the Company. In addition, solely for the purpose of covering over-allotments, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional 1,500,000 shares of Common Stock (the ‘‘Additional Shares’’). The Firm Shares and the Additional Shares are hereinafter collectively sometimes referred to as the ‘‘Shares.’’ The Shares are described in the Prospectus which is referred to below.
